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Lipopolysaccharides (LPS) are potent activator of the innate immune response through 
the binding to the myeloid differentiation protein-2 (MD-2)/toll-like receptor 4 (TLR4) 
receptor complexes. Although a variety of LPSs have been characterized so far, a detailed 
molecular description of the structure–activity relationship of the lipid A part has yet to be 
clarified. Photosynthetic Bradyrhizobium strains, symbiont of Aeschynomene legumes, 
express distinctive LPSs bearing very long-chain fatty acids with a hopanoid moiety 
covalently linked to the lipid A region. Here, we investigated the immunological proper-
ties of LPSs isolated from Bradyrhizobium strains on both murine and human immune 
systems. We found that they exhibit a weak agonistic activity and, more interestingly, a 
potent inhibitory effect on MD-2/TLR4 activation exerted by toxic enterobacterial LPSs. 
By applying computational modeling techniques, we also furnished a plausible expla-
nation for the Bradyrhizobium LPS inhibitory activity at atomic level, revealing that its 
uncommon lipid A chemical features could impair the proper formation of the receptorial 
complex, and/or has a destabilizing effect on the pre-assembled complex itself.
Keywords: lipopolysaccharide, innate immunity, inflammatory cytokines, myeloid differentiation protein-2/toll-like 
receptor 4, Bradyrhizobium lipid a, molecular modeling
inTrODUcTiOn
Lipopolysaccharides (LPSs) are amphiphilic molecules covering the outer membrane of most Gram-
negative bacteria. They are widely known to be involved in the elicitation of immune responses 
in eukaryotic organisms (1). Structurally, LPSs, in their smooth-form (S-LPS), are tripartite 
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macromolecules built up of a polysaccharide moiety, termed 
O-antigen, and a core oligosaccharide region covalently linked 
to a glycolipid domain termed lipid A; the latter is the most con-
served part and is responsible for the immunopotency exerted 
by LPSs isolated from pathogenic Gram-negative bacteria (2). 
In mammals, the lipid A component of the LPS is the primary 
immunostimulatory moiety of Gram-negative bacteria and 
acts as strong stimulator of the innate immunity. The endotoxic 
properties of the lipid A, namely its capacity to activate the 
host innate immune response, are strongly influenced by its 
primary structure. An overacting immune response, due to an 
uncontrolled and massive circulation of toxic LPS, can result in 
severe symptoms of sepsis and, in the worst case, septic shock 
and multi-organ failure. Interestingly, lipid A displaying moder-
ate to low agonist activity can operate as antagonist reducing or, 
in a dose-dependent manner, completely inhibiting a lipid A’s 
driven immune activation (1, 3, 4). Lipid A binds the receptor 
complex made up of toll-like receptor 4 (TLR4) and myeloid 
differentiation protein-2 (MD-2) on the plasma membrane of 
immune cells thus activating downstream signaling pathways 
leading to a rapid release of inflammatory cytokines (1, 5). The 
highest known immunostimulatory action on human cells is 
exerted by the bis-phosphorylated hexa-acylated lipid A from 
Escherichia coli, characterized by an asymmetric distribution 
of the acyl chains on the sugar backbone (Figure 1). Structural 
features such as the nature, number, and distribution of the fatty 
acid (FA) chains as well as the occurrence of phosphate units, 
greatly regulate its immunopotency; variation in the acylation 
or phosphorylation pattern corresponds to a decrease in the 
immunostimulatory (agonist) activity of the lipid A. One of the 
first known antagonistic lipid A species acting on the human 
MD-2/TLR4 complex is a tetra-acylated partial structure termed 
lipid IVA, a biosynthetic precursor of E. coli lipid A devoid of the 
secondary acyl moieties (6). The X-ray crystallographic structure 
of human MD-2/TLR4 with E. coli hexa-acyl LPS (7) provided 
the molecular basis of lipid A recognition by the MD-2/TLR4 
receptor complex. Briefly, five of the six FA chains of E. coli LPS 
are buried inside the lipophilic pocket of the MD-2 protein 
whereas the sixth acyl chain is partially extruded, lying on the 
surface and interacting with the partner TLR4 (dubbed TLR4*). 
This interaction is the basis for receptor complex dimerization, 
promoting the intracellular juxtaposition of the TIR domains and 
leading to signal transduction culminating in the elicitation of 
the inflammatory process. The X-ray crystallographic structure 
of the tetra-acylated lipid IVA in complex with human MD-2/
TLR4 receptor demonstrated that all four acyl chains are sitting 
inside the MD-2 binding pocket in a fashion that does not allow 
dimerization and subsequent activation (1, 8).
Noticeable efforts have been made so far to identify natural or 
ad hoc synthesized lipid A significantly different from enterobac-
terial counterparts and able to interfere or modulate immune/
inflammatory responses mediated by toxic lipid A, such as lipid 
IVA and Eritoran (1, 9). These lipid A variants are the most 
studied ligands of MD-2/TLR4, which is considered a molecular 
target related to several inflammatory pathologies but also to 
“modern-day” diseases, including allergies, asthma, and autoim-
mune disorders (10). However, the natural repertoire of LPSs is 
undeniably much more diverse, thus opening the possibility to 
find natural compounds to active as TLR4 immunomodulators 
or alternatively, to synthesize bio-inspired lipid A derivatives in a 
perspective of therapy-related drug design.
In this context, rhizobial lipid A remarkably differs from 
enterobacterial analogs in terms of acylation and phosphoryla-
tion pattern as well as in the sugar backbone. Previous studies 
reported indeed the weak endotoxic activity of rhizobial lipid A as 
well as its inhibitory properties toward the toxic effects of entero-
bacterial LPS (11–14), with the single exception of S. meliloti (15). 
Rhizobia are Gram-negative bacteria able to establish symbiotic 
relationship with legumes and to reduce atmospheric nitrogen 
into ammonium, thus providing nitrogen nutrition to the host 
plants (16, 17). Rhizobia belonging to the Bradyrhizobium genus 
are the most commonly found symbiont for most legume species 
in habitats worldwide and constitute the most commonly used 
inoculants for cultivated plants of first agronomic importance 
(as soybean, peanut, and cowpea) (18–20). Bradyrhizobium lipid 
A (21–24) (Figure 1), included the strains ORS278 and ORS285 
here used (25), comprises a mixture of species differing by the 
number, length, and nature of the acyl chains characterized by 
(i) a pentasaccharide sugar backbone; (ii) the occurrence of very 
long-chain fatty acids (VLCFA), which have been demonstrated 
to be pivotal in the bacterium adaptation to intracellular life 
(26–29); and (iii) a hopanoid moiety covalently linked to the 
VLCFA, present in a non-stoichiometric fashion.
The observation of expressing the unusual lipid A structure 
of Bradyrhizobia strains prompted us to evaluate the impact of 
Bradyrhizobium LPS/lipid A on the innate immune system. The 
results reported herein revealed an extremely low capability to 
elicit an immune response when tested on both murine and 
human cells. More intriguingly, a strong inhibitory activity toward 
the potent agonist E. coli LPS was observed. In order to shed light 
on this behavior, we also investigated the molecular basis of the 
mechanism of Bradyrhizobium LPS/lipid A binding to the human 
MD-2/TLR4 complex by computational approach, with the aim 
to provide a molecular model explaining the antagonist proper-
ties of Bradyrhizobium lipid A.
With this work we meant to complement and expand previous 
studies highlighting the potential of rhizobia LPS as a promising 
natural source of MD-2/TLR4 immunomodulatory compounds, 
that can be of inspiration for development of vaccine adjuvants 
and/or endotoxin-based therapeutics as an alternative approach 
in the treatment of inflammatory disorders.
MaTerials anD MeThODs
heK 293 hTlr4/cD14/MD2 cell culture, 
Transfection, and stimulation
HEK293 cell line, stably transfected with human TLR4/MD2-CD14 
(InvivoGen) was seeded into 96-well plate at the concentration 
of 1 × 105 cells/mL. 48 h after seeding the cells were transiently 
transfected through PolyFect Transfection Reagent (Qiagen) with 
a reaction mix containing 150 ng of Firefly luciferase reporter con-
structs, pGL3.ELAM.tk [harboring nuclear factor kappa B (NF-κB) 
promoter sequences], and 15  ng of Renilla luciferase reporter 
FigUre 1 | Structure of the LPS lipid A from Escherichia coli (left) and Bradyrhizobium strains (right, HOLA). The tetra-acylated lipid A from E. coli (lipid IVA) lacks the 
two secondary acyl chains (light blue colored in the figure). HF-LA refers to hopanoid-free Bradyrhizobium lipid A and is devoid of the Hopanoid moiety (light green). 
The hexa-acylated lipid A from E. coli contains a bis-phosphorylated glucosamine disaccharide backbone, asymmetrically substituted by six acyl chains. 
Bradyrhizobia lipid A is mainly constituted of a mixture of hexa- and hepta-acylated species, possesses a 2,3-diaminoglucose (DAG) disaccharide backbone, a 
galacturonic acid residue on the vicinal DAG and an α-(1→6)-mannose disacchaccaride on the distal DAG. The acyl chains are asymmetrically distributed on the 
sugar skeleton; of the two secondary very long-chain fatty acids present, one is not stoichiometrically substituted at ω-1 position by a hopanepolyol acid.
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plasmid, pRLTK (as an internal control). The day after the cells were 
incubated with different concentrations of Bradyrhizobium lipid A 
or LPS [1, 10, and 100 ng/mL; the LPS and the lipid A preparations 
were obtained as previously described (21–24)], or with purified 
E. coli LPS (LPS-EB ultrapure; InvivoGen) or with synthetic lipid 
IVA used at the same concentrations as above, for 6 h to analyze 
NF-κB activity (Dual Luciferase Reporter Assay System, Promega) 
and to measure CXCL-8 release (DuoSet R&D System). For the 
competition assay, HEK 293-TLR4/MD2-CD14 cells were primed 
with 1, 10, and 100 ng/mL of Bradyrhizobium LPS or lipid A, or 
lipid IVA or with Shigella flexneri hexa-acylated LPS for 1 h and 
then exposed to E. coli LPS (10 and 100 ng/mL) for 4 h (30). After 
this time, NF-κB activity and CXCL-8 production were measured.
BMDMs isolation, culture, and stimulation
C57BL/6 mice were purchased from Charles River (Charles 
River ITALY). BMDMs were derived from the bone marrow cells 
collected from 5-week-old female mice, as already reported (31). 
Animal studies were conducted according to protocols approved 
by the University of Rome La Sapienza and adhered strictly to 
the Italian Ministry of Health guidelines for the use and care of 
experimental animals.
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BMDMs were differentiated during 7  days in RPMI 1640 
(Lonza, Italy), supplemented with 10% of heat-inactivated FBS 
(HycloneTM, Euroclone, Italy), 1% di l-glutamine (Lonza, 
Italy), 1% sodium pyruvate (Lonza, Italy), 1% NEAA (Lonza, 
Italy), 0.5% 2-ME (Gibco, Italy), and 40  ng/mL macrophage 
colony-stimulating factor (M-CSF; Miltenyi Biotec). BMDMs 
were seeded into 24-well plate (5 × 105 cells per well) and were 
incubated with different concentrations of Bradyrhizobium LPS 
or lipid A (1, 10, or 100 ng/mL) or with E. coli LPS or with lipid 
IVA at the same concentrations as above for 6 h. Where necessary, 
polyinosinic-polycytidylic acid, Poly (I:C) (Invivogen) was used 
at the concentration of 5 µg/mL. After this time the supernatants 
were collected and tumor necrosis factor TNF release was 
measured through ELISA (DuoSet R&D System). For the com-
petition assay, BMDMs were pre-incubated with Bradyrhizobium 
LPS or lipid A (10, or 100 ng/mL) or with lipid IVA at the same 
concentrations as above for 1 h and then exposed to E. coli LPS 
(10 ng/mL) for 4 h. After this time, TNF and CXCL-1 release was 
quantified via ELISA.
rna extraction and qPcr analysis of ifn-β 
expression
Total RNA was extracted from unstimulated or LPS or treated 
or Poly (I:C)-treated C57BL/6 BMDMs through Trizol reagent 
(Invitrogen) according to the manufacturer’s instructions. 
RNA was converted to cDNA using High Capacity cDNA 
Archive kit (Applied Biosystems, Monza, Italy) and random 
primers, and finally amplified using Power SYBR 17 Green 
PCR Master Mix (Applied Biosystem,). The 2−ΔΔCt method 
was applied to analyze the relative changes in expression 
profiling of interest genes, as already reported (32). Values 
were normalized to the internal tbp gene control. Primers for 
qPCR are for ifn-β: F-TCCGAGCAGAGATCTTCAGGAA; 
R-TGCAACCACCACTCATTCTGAG. For tbp: F-CTG GAA 
TTG TAC CGC AGC TT; R-TCC TGT GCA CAC CAT TTT TC.
human Peripheral Blood Mononuclear 
cells (PBMcs) isolation and stimulation
Peripheral blood mononuclear cells were isolated from buffy coats 
obtained by the blood bank of Sapienza University from healthy 
adult volunteers (blood donors) following written informed 
consent. CD14+ monocytes were isolated from PBMCs using the 
MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
cultured in complete RPMI 1640 medium (Lonza, Italy, Milan), 
supplemented with 10% of heat-inactivated FBS (HycloneTM, 
Euroclone, Italy, Milan), 1% di l-glutammine (Lonza), 1% of 
non-essential amino acid solution (NEEA—Lonza), 1% sodium 
pyruvate (Lonza), penicillin 100 U/mL–streptomycin 100 µg/mL 
(Lonza), and 0.1% di 2-ME (Gibco, Italy). CD14+ monocytes 
were seeded at the concentration of 5 × 105 cells/well in 12-mul-
tiwell plate and exposed to 0.05, 0.5, 1, and 10 ng/mL of LPS or 
lipid A from Bradyrhizobium or to commercial E. coli O111:B4 
or to synthetic lipid IVA at same concentrations as above for 12 h. 
Cell supernatants were then collected and processed for ELISA to 
measure the levels of TNF and IL-6.
cytokine Measurement
Murine and human cytokines were determined in supernatants 
of stimulated cells by using R&D Systems DuoSet ELISA kits 
according to the manufacturers’ instructions.
Molecular Modeling
Structure Construction
The 3D structures of both the hopanoid-containing and HOLA 
and HF-LA were built with PyMOL molecular graphics and 
modeling package based on the saccharide backbone of E. coli 
LPS retrieved from the PDB ID 3FXI. Atoms were modified 
and added accordingly and bond type and length were care-
fully selected and revised. The geometry of these two struc-
tures was further optimized with Maestro under the OPLS3 
force field. The antagonist conformation of the hTLR4/MD-2 
complex was assembled by merging the ectodomain of TLR4 
from RCSB (www.rcsb.org) PDB ID 3FXI and MD-2 from PDB 
ID 2E59. The latter was aligned to the spatial coordinates of 
the MD-2 present in 3FXI and solvent, ligands, and ions were 
removed.
Structure Optimization
Hydrogen atoms were added to the X-ray structures using the pre-
processing tool of the Protein Preparation Wizard of the Maestro 
package, and then the structures went through a restrained 
minimization under the OPLS3 force field with a convergence 
parameter to RMSD for heavy atoms kept default at 0.3 Å.
Docking Procedure
Gasteiger charges were computed and assigned with 
AutoDockTools 1.5.6 to both the proteins and the ligands. Both 
HOLA and HF-LA were left flexible by allowing some appropri-
ately selected dihedral angles to rotate whereas the receptor was 
always kept completely rigid. The docking was performed with 
AutoDock Vina (33). A cubic docking box of 60 Å in size and 1 Å 
in spacing was defined. The box was centered equidistant to the 
geometric center of residues Arg90 (MD-2), Arg96 (MD-2), and 
Arg264 (TLR4).
Parameterization
The full lipid structures were split into residues to facilitate and 
homogenize the parameterization process. The partial charges and 
atom types of the 4-substituted and the 6-substituted 2,3-diamino-
2,3-dideoxy-glucose (DAG) monosaccharides composing the 
oligosaccharide backbone were established respectively based 
on residues 4YB (4-substituted GlcNAc) and 6YA (6-substituted 
GlcNAc) of the GLYCAM force field (34). The partial charges 
and parameters for the two mannose (Man) residues and the 
galacturonic acid (GalA) were retrieved from the GLYCAM force 
field respectively under the name 0MA, 6MA, and 1OA. Partial 
charges for the primary and secondary acylation as well as for 
the hopanoid residue were derived, with the help of antechamber 
(31), following the standard GAFF procedure described in the 
AMBER manual and the parameters were assigned by the GAFF 
force field.
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MD Simulations
All MD simulations were performed with AMBER14 (35), the 
protein was described by the ff14SB all-atom force field (36), 
the pentasaccharide backbone of the BTAi1 lipid A by the 
GLYCAM_06j-1 force field (34) and the other constituents of 
the lipid A (the lipid chains and the hopanoid moiety) were 
parameterized with the General Amber Force Field (GAFF) 
(37). The simulation box was designed such as the edges are dis-
tant of at least 10 Å of any atoms. The system was solvated with 
the TIP3P water molecules model. One Na+ ion was added to 
counterbalance the negative charge of the galacturonate group. 
All the simulations were performed with the same equilibration 
and production protocol. The equilibration protocol contains 
height sequential steps. The first one consists of 1,000 steps of 
steepest descent algorithm followed by 7,000 steps of conjugate 
gradient algorithm; a 100  kcal mol−1.Å−2 harmonic potential 
constraint is applied on both the proteins and the ligand. In 
the fourth subsequent steps, the harmonic potential is progres-
sively lowered (respectively to 10, 5, 2.5, and 0 kcal mol−1.Å−2) 
for 600 steps of conjugate gradient algorithm each one. In the 
sixth step, the system is heated from 0–100  K by a Langevin 
thermostat in the canonical ensemble (NVT) under a 20 kcal 
mol−1.Å−2 harmonic potential restraint on the proteins and the 
ligands. The next step heats up the system from 100–300  K 
in the isothermal-isobaric ensemble (NPT) under the same 
restraint condition than the previous step. In the last step, the 
same parameters are used to simulate the system for 100 ps but 
no harmonic restraint is applied. At this point, the system is 
ready for the production run, which is performed in the NPT 
ensemble.
resUlTs
immunomodulatory Properties of 
Bradyrhizobium lPs and lipid a
Immunological Tests of Bradyrhizobium LPS and 
Lipid A on HEK293 hTLR4 Cell Line
To evaluate the immunological impact of Bradyrhizobium LPS 
and eventually lipid A, we first analyzed their effect at different 
concentrations (1, 10, and 100 ng/mL) in the HEK293 cell line 
(38), stably transfected with human CD14/MD-2/TLR4. Similar 
concentration of the hexa-acylated, highly stimulatory LPS of 
E. coli O111:B4 and the synthetic lipid IVA were used as agonistic 
and antagonistic controls, respectively. Likewise, untreated cells 
were considered as the negative control in all the experiments 
shown. Stimulation of HEK293 hTLR4 was carried out for 6 h 
(Figures 2A,B).
With a parallel approach, we used HEK293 hTLR2 cells to 
assess whether the biological activity of Bradyrhizobium LPS 
could be extended to TLR2, in addition to TLR4 as described for 
a limited number of LPS (Figure S1A in Supplementary Material) 
(39). Furthermore, assessment of the Bradyrhizobium LPS in this 
cell model could rule out a potential role for lipopeptides L(Ps) 
contaminating LPS. In HEK293 hTLR2 cells, Pam3CSK4 (Pam3) 
(500 ng/mL), a synthetic triacylated lipopeptide (LP) that mim-
ics the acylated amino terminus of bacterial LP, represented the 
positive control for a TLR2 ligand. Cells treated with E. coli LPS, 
as above, or untreated cells were used as the negative controls. 
Activation of NF-κB and Chemokine (C-X-C motif) ligand 8 
(CXCL-8, also known as IL-8) production was measured after 
6  h of stimulation in both assays. As shown in Figures  2A,B, 
stimulation of HEK293 hTLR4 with Bradyrhizobium LPS and 
lipid A stimulation elicited a poor NF-κB activation and CXCL-8 
production, which were significantly lower with respect to the 
values induced by E. coli LPS stimulation (for NF-κB and CXCL-
8, Bradyrhizobium LPS at 10 and 100 ng/mL vs. E. coli LPS at same 
concentrations p < 0.001). No activation of NF-κB and CXCL-8 
production (Figures S1A,B in Supplementary Material) were 
observed upon HEK293 hTLR2 stimulation with Bradyrhizobium 
LPS and lipid A, suggesting that neither LPS nor lipid A could 
trigger the TLR2-mediated signaling.
Immunological Impact of Bradyrhizobium LPS and 
Lipid A on CD14+ Derived Monocytes Derived From 
PBMCs
The low immunological impact of Bradyrhizobium LPS and lipid 
A was also confirmed in human CD14+ derived monocytes 
derived from PBMCs, which express all TLRs. Cells were exposed 
to Bradyrhizobium LPS and lipid A at the concentration of 0.05, 
0.5, 1, and 10 ng/mL for 12 h. E. coli LPS was tested in parallel 
at same concentrations. The release of the pro-inflammatory 
cytokines TNF and interleukin-6 (IL-6) was assessed as readout. 
The results are shown in Figures  2C,D. In agreement to what 
observed in the HEK293 hTLR4 cell model, with Bradyrhizobium 
lipid A the release of these cytokines was poorly detectable at any 
concentration tested while 10 ng/mL Bradyrhizobium LPS clearly 
induced TNF and IL-6, albeit both were significantly lower than 
those elicited by E. coli LPS at the same concentration (for TNF, 
Bradyrhizobium LPS at 1 and 10 ng/mL vs. E. coli at same LPS 
concentration p < 0.001; for IL-6, all Bradyrhizobium LPS con-
centrations vs. E. coli all concentrations p < 0.001).
Immunological Impact of Bradyrhizobium LPS and 
Lipid A on BMDMs From C57BL/6 Cells
To strengthen the results obtained in the HEK293 cell models 
and PBMCs, we also used BMDMs from C57BL/6 wild-type 
mice or from C57BL/6 knockout mice for Tlr2 (Tlr2−/−) or Tlr4 
(Tlr4−/−) (Figures S1C,D in Supplementary Material). Murine 
macrophages were exposed to Bradyrhizobium LPS and lipid A 
at 1, 10, and 100 ng/mL. Pam3 (1 µg/mL) and E. coli LPS at the 
same concentrations as above, were the positive controls for TLR2 
and TLR4, respectively. After 6 h stimulation, TNF production 
was quantified. In wild-type macrophages, stimulation with 
either Bradyrhizobium LPS or lipid A induced significantly less 
TNF compared to stimulation with Pam3 (all Bradyrhizobium 
LPS concentrations vs. E. coli all concentrations p <  0.001) as 
shown in Figure  2E. As observed in PBMCs, Bradyrhizobium 
LPS and lipid A induced a scantly amount of this cytokine (all 
Bradyrhizobium LPS and lipid A concentrations vs. E. coli all 
concentrations p < 0.001).
When the same experimental set-up was applied to murine 
macrophages of tlr2−/− or tlr4−/− mice, we found that the 
FigUre 2 | Analysis of immunopotential of Bradyrhizobium LPS/lipid A in HEK293 hTLR4 cell line, monocytes, and BMDMs. Activation of nuclear factor kappa B 
(a) and CXCL-8 production (B) in HEK 293 hTLR4/MD2-CD14 stimulated with Bradyrhizobium LPS/lipid A at the concentration of 1, 10, and 100 mg/mL for 6 h. 
Commercial hexa-acylated Escherichia coli LPS or synthetic lipid IVA were used at the same concentrations as positive and negative control, respectively. tumor 
necrosis factor TNF (c) and IL-6 (D) release in cell-free supernatants of monocytes stimulated with Bradyrhizobium LPS/lipid A at the concentration of 0.05, 0.5, 1, 
and 10 mg/mL for 12 h. Commercial hexa-acylated E. coli LPS was used at the same concentrations as control. TNF (e) production in BMDMs stimulated with 
Bradyrhizobium LPS/lipid A at the concentration of 1, 10, and 100 mg/mL for 6 h. Abbreviation: NS: not stimulated. Data are expressed as mean ± SD of three 
independent experiments in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001, after Student’s t-test.
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absence of tlr2 prevents the production of TNF upon Pam3CSK 
stimulation but not following LPSs and lipid A stimulation, as 
expected. On the contrary, in tlr4−/− mice TNF production 
was null and high following LPSs/lipid A and Pam3 stimulation, 
respectively (Figures S1C,D in Supplementary Material). These 
results confirm those achieved in the HEK293 cell models: i.e., 
the reduced immunostimulatory of Bradyrhizobium LPS and 
lipid A is strictly dependent on TLR4 and not on TLR2.
Downstream TLR4-mediated LPS signaling two pathways 
could be activated. The adaptor protein MyD88 engages a path-
way leading to the production of pro-inflammatory cytokines, 
such as TNF and CXCL-1. The other pathway involves the 
FigUre 3 | Assessment of the involvement of Trif pathway upon stimulation of BMDMs with Bradyrhizobium LPS/lipid A. Inducible protein 10 (a) and CCL-5 
production (B) in BMDMs stimulated with Bradyrhizobium LPS/lipid A at the concentration of 1, 10, and 100 ng/mL for 6 h. Commercial hexa-acylated Escherichia 
coli LPS or synthetic lipid IVA were used at the same concentrations. The TLR3 agonist poly (I:C) (5 µg/mL) was used as a positive control of Trif pathway activation. 
Data are expressed as mean ± SD of three independent experiments in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001, after Student’s t-test. (c) qPCR of ifn-β 
mRNA following 3 h of stimulation of BMDMs with LPS/lipid A at the same concentrations, as above. Results are normalized to the internal TBP gene control and 
are presented on a logarithmic scale as the ratio of gene expression between stimulated and unstimulated BMDMs.
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proteins Mal (also called TIRAP), TRIF, and TRAM, allowing the 
expression of genes encoding type 1 interferon and interferon-
associated genes (40, 41). Therefore, we faced the question of 
whether Bradyrhizobium LPS and/or lipid A could activate the 
Trif pathway. With this aim, BMDMs were stimulated as above 
with 1, 10, or 100  ng/mL of Bradyrhizobium lipid A or LPS. 
E. coli LPS and lipid IVA were used at same concentrations as a 
control. Polyinosinic-polycytidylic acid, Poly (I:C)—a synthetic 
analog of double stranded RNA—which acts as TLR3 agonist was 
used at the concentration of 5 µg/mL to elicit the Trif pathway. 
After 6 h of stimulation, we measured the release of the cytokine 
interferon inducible protein 10 (IP-10), which is induced by the 
axis LPS-TRIF-IRF3-IFN (42) and the chemokine RANTES 
(CCL-5,) which is expressed through the involvement of IRF3 
(43, 44). Bradyrhizobium lipid A and lipid IVA did not elicit any 
IP-10 release while Bradyrhizobium LPS at the concentration of 
100 ng/mL could induce a low production of IP-10, which was 
significantly lower than those observed with E. coli LPS at the 
concentrations of 10 and 100  ng/mL and Poly (I:C) (for both 
p < 0.001), as shown in Figure 3A. The same trend was observed 
for CCL-5 (Figure  3B). As IFN-β release can be undetect-
able upon BMDM stimulation with the fully immunocompetent 
hexa-acylated E. coli LPS (30) we directly proceeded to analyze 
the mRNA levels for this cytokine. BMDMs were stimulated with 
1, 10, or 100 ng/mL of Bradyrhizobium LPS or lipid A or with E. 
coli or with lipid IVA at the same concentrations. Poly (I:C) was 
used as above. After 3 h of stimulations BMDMs were processed 
to measure the levels of ifn-β RNA through qPCR. In accordance 
with results of IP-10 and CCL-5 release, ifn-β RNA was undetect-
able with Bradyrhizobium lipid A while Bradyrhizobium LPS at 
the concentration of 100 ng/mL could trigger a low expression of 
ifn-β (Figure 3C). As expected, E. coli LPS and Poly (I:C) deter-
mined high levels of ifn-β RNA. Definitely, these data suggest that 
Bradyrhizobium LPS is a poor elicitor of the Trif pathway.
Competition Tests of Bradyrhizobium LPS and Lipid 
A on HEK293 hTLR4 and on C57BL/6 BMDMs Cell 
Lines
Finally, as some under-acylated lipid A (45) and, more recently, 
unusual LPS-containing long FA chains (46), have been reported 
to show an inhibitory activity against endotoxically active LPS 
(47), we assessed the ability of Bradyrhizobium LPS to affect 
the TLR4-mediated signaling triggered by the hexa-acylated, 
fully immunocompetent E. coli LPS. With this aim, HEK 293 
FigUre 4 | Competition assay: (a–D) HEK293 hTLR4 cell line; (e,F) BMDMs. (a,B) Fold of nuclear factor kappa B activation and (c,D) CXCL-8 release following 
priming with 10 and 100 ng/mL of Bradyrhizobium LPS or lipid A, or with lipid IVA or with Shigella flexneri hexa-acylated LPS for 1 h and then exposed to Escherichia 
coli LPS (10 and 100 ng/mL) for 4 h. Stimulation with the only E. coli LPS (10 and 100 ng/mL) for 5 h was used as a control. (e,F) BMDMs were stimulated with 10 
and 100 ng/mL of Bradyrhizobium LPS or with lipid IVA during 1 h and then incubated with 10 ng/mL of E. coli LPS for 4 h. After this time TNF and CXCL-1 release 
were quantified. Stimulation with the only E. coli LPS (10 ng/mL) for 5 h was used as a control. Data are expressed as mean ± SD of three independent experiments 
in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001, after Student’s t-test.
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hTLR4 cells were pre-incubated for 1  h with Bradyrhizobium 
LPS and stimulated with 10 and 100  ng/mL of E. coli LPS for 
4 h (Figures 4A–D). NF-κB activation and CXCL-8 production 
were quantified after this time. The synthetic tetra-acylated 
lipid IVA was used in parallel under the same conditions as 
for Bradyrhizobium LPS as a control of the inhibitory effect. A 
hexa-acylated LPS of Shigella flexneri (30) was used in parallel. 
Untreated cells and cells stimulated with the E. coli LPS at 10 and 
FigUre 5 | Best docked poses for HF-LA, represented in green sticks (on the left), and HOLA, in yellow sticks and the hopanoid residue in orange (on the right), 
inside myeloid differentiation protein-2 (MD-2) structure. Lipid IVA, added for comparison purposes, is depicted in pink CPK colored semi-transparent sticks. MD-2 is 
in blue semi-transparent cartoon. Some residues mentioned in the text are in sticks with their corresponding individual labeling.
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100 ng/mL for 4 h were the control in this experiment. Under 
these experimental conditions, Bradyrhizobium LPS showed an 
inhibitory activity on E. coli LPS at all the concentrations tested 
(NF-κB values of Bradyrhizobium LPS +  E. coli LPS vs. E. coli 
LPS alone, for NF-κB; Bradyrhizobium LPS at 1 and 10 ng/mL 
p < 0.001; Bradyrhizobium LPS at of 100 ng/mL p < 0.01).
Finally, we evaluated whether Bradyrhizobium LPS could also 
interfere with TLR4 signaling in murine cells which have been 
reported to be less sensitive to the degree of lipid A acylation 
(48, 49). Therefore, BMDMs were stimulated with 10 and 100 ng/
mL of Bradyrhizobium LPS for 1 h and then exposed to 10 ng/
mL of E. coli LPS for 4 h (Figures 4E,F). Unstimulated cells and 
BMDMs stimulated with 10 ng/mL E. coli LPS for 5 h were the 
controls. The production of TNF and CXCL-1 was measured. 
As shown in Figures  4E,F under these conditions only the 
concentration of 10 ng/mL exerted an inhibitory effect on the E. 
coli LPS (p < 0.01).
Molecular Modeling of Bradyrhizobium 
lipid a Binding to MD-2/Tlr4
We performed computational studies to identify the pos-
sible binding modes and understand the dynamic behavior 
of Bradyrhizobium lipid A (Figure  1) in complex with human 
MD-2/TLR4. Since the experimental samples contain different 
derivatives, we studied both hopanoid-containing and hopanoid-
free Bradyrhizobium lipid A (HOLA and HF-LA respectively, 
Figure 1). Docking results were evaluated based on the predicted 
binding score and on the apparent degree of similarity with E. 
coli LPS and lipid IVA as known from their X-ray crystallographic 
structures accessible under the PDB accession codes 3FXI and 
2E59, respectively. We considered both the insertion of the FA 
chains into the MD-2 pocket and the positioning of the disac-
charide backbone. In addition, we systematically discarded the 
poses in which at least one of the saccharide-bearing acyl chains 
was rotated such as that the amide groups connecting the saccha-
ride to the lipid chains were facing the opposite direction of the 
binding pocket. This orientation causes a large portion of the lipid 
chains to be exposed to the solvent, which we consider unlikely.
Docking Calculations of HF-LA and HOLA in MD-2
We started by carrying out docking calculations of HF-LA and 
HOLA in MD-2. Plausible binding modes were obtained with 
most of the FA chains inserted inside the MD-2 pocket, while the 
sugar moieties interact at its rim. As for the interactions, in the 
case of HF-LA, the two VLCFA are often fully accommodated 
inside the MD-2 cavity where they are surrounded by hydropho-
bic residues, such as Val24, Ile32, 46, 63, 94, 117, 153, and Leu61, 
78, leaving space for only two shorter lipid chains to enter the 
pocket. One of the two remaining shorter chains is often directed 
toward Phe126. The other one is placed in a small corridor point-
ing at Ser103 (Figure 5).
In the case of HOLA, the hopanoid moiety lies at the rim 
of the MD-2 pocket close to the residues Asp101, Tyr102, and 
Ser118 (Figure  5) or at a completely distinct location close to 
residue Lys125 and Phe126. In many docked poses, the hopanoid 
moiety remains on a surface outside or at the rim of the MD-2 
pocket. Some low-score docking poses feature the hopanoid 
moiety in the hydrophobic pocket, proving that it could steri-
cally be accommodated inside MD-2. However, in these poses, 
the pentasaccharide backbone is accommodated further away 
from the binding pocket, on a loop followed by a β-sheet formed 
by residues 87–91 (Figure S2 in Supplementary Material). This 
is likely due to the steric constraints inherent to the hopanoid 
moiety being inserted in the pocket. In addition, it occupies a 
consequent volume and seems to obstruct the passage for the 
lipid chains, resulting in poses in which at least three acyl chains 
are left outside the pocket. These results suggest that the hopanoid 
moiety may not play a particularly important role in the effective 
binding of HOLA to MD-2, and thus its presence might not be 
necessary for Bradyrhizobium to exert its antagonist activity.
Docking Calculations and MD Simulation of 
Bradyrhizobium Lipid A Into MD-2/TLR4 Model
In a second approach, docking calculations of HOLA were 
performed into the MD-2/TLR4 model in the antagonist confor-
mation reported by us somewhere else (50). Interestingly, when 
compared with the structure of the MD-2/TLR4 complex in the 
FigUre 6 | Representation of the steric clash observed over the superimposition of the myeloid differentiation protein-2 (MD-2)/HOLA complex (from docking 
calculations) to the MD-2/toll-like receptor 4 (TLR4) structure (from PDB ID 3FXI). A general view of the MD-2/TLR4/HOPA complex (a) and two examples of steric 
clashes are given (B,c). TLR4, MD-2, and HOPA are respectively represented in gray cartoon, blue cartoon, and yellow sticks. The TLR4 protruding loop mentioned 
in the text is marked within the red circle, involving the hopanoid moiety (B) and one of the short acyl chains of HOPA (c).
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agonist conformation (PDB ID 3FXI), among the non-bonded 
interactions between the two proteins, a loop of TLR4, composed of 
amino acids 263–266, protrudes into a MD-2 channel (Figure S2 in 
Supplementary Material), located approximately between Asp161 
and Tyr118. This protrusion is further amplified by the side chain 
of Arg264 that goes as far as to hover over the MD-2 hydrophobic 
pocket. This impingement of TLR4 over MD-2 diminishes the 
space available for ligand interactions in the MD-2/TLR4 complex 
compared with MD-2 alone. We superimposed TLR4, based on the 
X-ray crystallographic structure (PDB ID 3FXI), to the docking 
results from the MD-2-only study and noted a steric incompat-
ibility between the TLR4 protruding loop, and either a lipid chain 
or the hopanoid moiety from the docked ligand (Figure 6). This 
observation could point to the fact that HOLA and HF-LA carry 
on their antagonist activity by preventing or impairing the forma-
tion of a proper MD-2/TLR4 dimer essential for TLR4 activation.
The hydrophobic interactions taking place inside the hydro-
phobic pocket were essentially the same as the ones described in 
the case of MD-2 alone. However, the presence of TLR4, reducing 
the space available for ligand binding, resulted in very few poses 
respecting the sugar orientation criterion mentioned above. Two 
poses of HOLA, in good agreement with lipid IVA, were selected 
for MD simulations to further investigate interactions with the 
receptor and the overall stability of the MD-2/TLR4/ligand com-
plex (Figure 7). These two poses are rotated 180° one to the other: 
in the first one, the HOLA lipid A is oriented as lipid IVA (PDB ID 
2E59) and, in the second one, it is oriented as E. coli LPS (PDB ID 
3FXI, Figure S2 in Supplementary Material). Along the simulation 
time, the TLR4 presents important deviation compared to the 
crystal structure in relation with MD-2, as shown in the RMSD 
plot (Figure S4 in Supplementary Material). TLR4 displays a 
tendency to break apart from MD-2 indicating that the presence 
of the ligand destabilizes the TLR4/MD-2 complex (Figure 8).
This observation backs-up the hypothesis that Bradyrhizobium 
lipid A act as antagonists by either preventing complex formation 
(cf. protruding loop mentioned in the docking study above) or 
by disturbing the complex stability. In addition, Phe126 remains 
in its open conformation all along the simulation (Figure S4 in 
Supplementary Material), this stability was previously associated 
with antagonist ligands (51).
DiscUssiOn
LPS is among the most potent pro-inflammatory compounds 
known, with its lipid A moiety eliciting the production of host-
derived inflammatory mediators. Pyrogenicity and lethality of 
lipid A strictly relies on a set of structural features which includes 
the number and distribution of appropriately long acyl chains 
with respect to the glucosamine disaccharide backbone as well 
as the occurrence of phosphate units decorating the sugar back-
bone (52, 53). The possibility to prevent the detrimental effects 
of toxic LPS by competing lipid A derivatives with a weak or no 
FigUre 8 | Evolution of the myeloid differentiation protein-2 (MD-2)/toll-like receptor 4 (TLR4)/HOPA complex (blue/violet/yellow) over the MD simulation. MD-2/
TLR4 structure from PDB ID 3FXI, represented in semi-transparent cartoon (gray), was superimposed for comparison purposes. On the left: system at t = 0 ns, from 
the docking calculation. On the right: system at t = 100 ns of MD simulation.
FigUre 7 | Representation of the two poses of HOPA (yellow) docked into myeloid differentiation protein-2/toll-like receptor 4 (blue/violet), Escherichia coli lipid 
A-like (on the left) and lipid IVA-like (on the right), selected for MD simulations.
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immunostimulant power is a hot topic with an increasing appeal 
in several research fields (54, 55). In this context, one of the most 
studied is the set of synthetic analogs of lipid A of Rhodobacter 
capsulatus or Rhodobacter sphaeroides which are known to act as 
antagonists toward toxic effects of enterobacterial LPS on human 
cells (56–58).
Within this frame, we have recently shown that Bradyrhizobium 
lipid A present peculiar structural features comprising a penta-
saccharide backbone formed by a skeleton of β-(1→6) linked 
2,3-diamino-2,3-dideoxy-glucose (DAG) substituted by an 
α-GalA on the vicinal DAG and by an α-mannose disaccharide 
linked to the distal β-DAG unit (21–25); the LPS exhibits a hetero-
geneous blend of lipid A species, in terms of number and nature 
of acyl chains asymmetrically distributed on the sugar skeleton 
and contains VLCFA. Furthermore, as a unique peculiarity, 
Bradyrhizobium strains lipid A displays the covalent attachment 
of a hopanoid molecule to a VLCFA (21).
Given the not human pathogen/human associated nature of 
Bradyrhizobium strains, the unusual structural features of its lipid 
A, in addition to the still unresolved mechanisms at the basis of 
rhizobial LPS immunoactivity, prompted the investigation of 
the immunological properties of such a complex and novel mol-
ecule which turned out to act as a very weak agonist of murine 
and human immune cells. More importantly, we proved that 
Bradyrhizobium LPS is able to potently inhibit the toxic effects 
of E. coli LPS on both murine and human immune systems as 
a significant decrease in the cytokine release and NF-kB activa-
tion were clearly observed when cells were stimulated with both 
Bradyrhizobium LPS and lipid A and then re-stimulated with the 
toxic E. coli or S. flexneri LPS. We found that the inhibitory effect 
is especially evident at low Bradyrhizobium LPS concentrations. 
This is not surprising since this LPS is constituted by several lipid 
A species as mentioned above. We can hypothesize that this blend 
could contain one/some species provided of an inhibitory activ-
ity and others deprived of this property. By increasing the LPS 
concentration, the effect of these latter species prevails on that of 
the antagonistic species thus lowering the inhibitory capacity of 
this LPS. We observed the same effect with other LPS blends such 
as that of the intracellular S. flexneri (30) on E. coli LPS. Lipid A 
structures such as those of Pseudomonas aeruginosa, Bordetella 
pertussis, Leptospira interrogans, and Neisseria meningiditis are 
differently recognized by mouse and human TLR4 (48, 49). The 
acylation degree, the phosphate presence/absence or substitution 
and other still unknown molecular features of lipid A underline 
the differential recognition by the human and murine TLR4 
complex. In line with this issue, here the inhibitory activity of 
Bradyrhizobium LPS seems to be more evident when tested on 
human TLR4 than on murine TLR4 (see Figures 2A,E) in this 
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way stressing this difference. Furthermore, we also showed that 
Bradyrhizobium lipid A acts exclusively through TLR4 and do 
not activate TLR2 at all, in accordance with data from other lipid 
A strains (59). These immunological properties, as stated above, 
can be correlated to the peculiar structure of rhizobial LPS which 
showed uncommon sugar backbone, lacking phosphate decora-
tion and presenting, among the others, VLCFA with a chain 
length ranging from 26 to 32 carbon atoms. In support to the 
hypothesis that VLCFA are involved in the potent TLR4 inhibi-
tory activity observed for some rhizobial LPSs, a recent study 
showed that the human pathogen Bartonella quintana, expressing 
a penta-acylated lipid A decorated by one VLCFA [namely 26:0 
(25-OH)], was able to potently block TLR4 activation by rapidly 
and protractedly binding the receptor complex (46). Interestingly, 
other intracellular pathogens belonging to Brucella (60, 61) and 
Legionella (62, 63) species and phylogenetically related opportun-
istic bacteria like Ochrobactrum contain VLCFA in their lipid A; 
in all these species, the low immunopotential of their lipid A LPS 
likely favors the escape from the innate immune system and the 
intracellular entry, as already demonstrated for other intracellular 
living bacteria as Shigella (30).
To shed light on this behavior, we investigated the molecular 
basis of the Bradyrhizobium lipid A binding to the MD-2/TLR4 
complex (64). Our computational data demonstrated that the 
occurrence of VLCFA, likely fully accommodated inside the 
MD-2 cavity, may be responsible for the antagonistic properties 
of Bradyrhizobium lipid A by impairing the proper complexation 
of the TLR4/MD-2 dimer or potentially by destabilizing the 
complex itself, and, furthermore, do not point toward a primary 
role of the hopanoid moiety in the biological activity regarding 
TLR4 signaling. Our results suggest that the TLR4 signaling 
modulation is likely to occur by direct interaction with the TLR4/
MD-2 complex, both in its hopanoid-containing and hopanoid-
free forms. We indeed derived plausible binding modes of both 
HOLA and HF-LA to the MD-2/TLR4 system, demonstrating 
that Bradyrhizobium lipid A can act as antagonist by either pre-
venting complex formation or by disturbing the complex stability, 
this accounting for the potent activity antagonizing E. coli LPS 
binding to the MD-2/TLR4 complex thus inhibiting its toxic 
effects. A clear understanding, at atomic level, of the molecular 
mechanisms leading to TLR4 activation/inhibition upon bind-
ing of Bradyrhizobium LPS can be of help in future prediction 
of the immunomodulatory properties of LPSs, and consequently 
of their potential use in biomedical applications, based on the 
chemical features of the lipid domain.
In summary, our work certainly confirmed that the rhizobia 
LPS world is a promising source of MD-2/TLR4 immunomodu-
lators, that can be instrumental for the rational development 
of endotoxin-based therapeutics and/or vaccine adjuvants. 
Indeed, weak agonists, as Bradyrhizobium LPS has shown to be, 
are typically desired to be used as adjuvants in vaccine produc-
tion, whereas antagonists, as stated above, are being sought as 
inhibitors of TLR4-dependent signaling to fight against sepsis 
(65). This becomes even more appealing under another point 
of view focused on the growing body of information describing 
the involvement of LPS and TLR4 in development of strongly 
emerging pathologies such as allergies. Indeed, it has been dem-
onstrated that exposure to high concentrations of LPS induces 
allergic airway inflammation symptoms and disease via TLR4 
signaling (66, 67). On the contrary, it has been demonstrated 
that environmental exposure to LPS can exert a protective action 
against the development of atopy and asthma (10). More interest-
ingly, allergy-protective activity by the hepta-acylated LPS from 
the farm environmental bacterium Acinetobacter lwoffii F78 has 
been previously described and compared to other structurally 
different LPSs, such as the canonical hexa-acylated LPS from 
E. coli, which showed apparently no protective properties in 
concentrations comparable to a farming habitat (68). It would be 
tempting to say that the identification of new immunomodula-
tory compounds with a weak immunostimulant activity on TLR4 
as well as an inhibitory action of harmful LPSs might also open 
to prevention of such diseases caused by abnormally exacerbated 
reactions to environmental factors. Therefore, determining and 
understanding how structural features of LPSs may affect the 
activation/modulation of the immune response may provide the 
mechanism for the fine tuning of the response itself as well as new 
insights to immunomodulatory processes.
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